drugset / Trial / NCT02546739
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Phase 1
Unknown
100 enrolled
Beijing Doing Biomedical Co., Ltd.
Hebei Yanda Ludaopei Hospital · collabThe First Hospital of Jilin University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2022-03-01
- Completion
- 2023-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD19-CAR | Cell therapy | — | — |